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Antimicrobial peptides (AMPs) are a class of promising anti-infective molecules but their 
therapeutic application is opposed by their poor bioavailability, susceptibility to protease 
degradation and potential toxicity. The advancement of nanoformulation technologies offers 
encouraging perspectives for the development of novel therapeutic strategies based on AMPs to 
treat antibiotic resistant microbial infections. Additionally, the use of polymers endowed per-se 
with antibacterial properties, stands out as an innovative approach for the development of a new 
generation of drug delivery systems in which an enhanced antimicrobial action could be obtained by 
the synergic combination of bioactive polymer matrices and drugs. Herein, the latest AMPs drug 
delivery research is discussed. 
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Severe diseases related to microbial infections and contaminations are of great concern in various 
areas, such as medical devices, drugs, hospitals, dental office equipment, food industry, packaging 
and storing, etc. Generally, these infections are treated with antimicrobial agents and are susceptible 
to their action. Particularly problematic are microorganisms that rapidly and easily gain resistance 
to conventional antimicrobial drugs, making them insusceptible to conventional drugs and leading 
to difficult pathogen eradication [1]. At least one mechanisms of resistance, but often more than 
one, has been developed for each one of the 17 different classes of antibiotics produced to date. 
Moreover, the ability of bacteria to develop simultaneous resistance to two or more antibiotic 
classes has made the treatment of such infections extremely difficult, very costly and associated, in 
many cases, with high morbidity and mortality [2]. The alarming rise in antibiotic resistance, has 
led to the selection of pan drug-resistant microorganisms (PDR) that are resistant to all available 
antibiotics. The inability to treat infections caused by such pan-resistant bacteria, is keeping 
infectious diseases among the major public health issues and poses substantial challenges to the 
human welfare [3]. Bacterial esistance causes only in the European Union about 25.000 deaths per 
year, with an overall societal cost of €1.5 billion per year [3, 4]. 
Development of multiple drug resistance enforces administration of high-dose of conventional 
antibiotics leading to adverse side effects and intolerable toxicity. Alternative strategies to treat 
microbial diseases such as the use of potent and/or specific antimicrobial systems would help to 
mitigate, treat and/or eradicate these infections, with an improvement in the state of well-being. 
Among them, novel molecules and nanoscale materials have emerged as novel antimicrobial agents. 
In this context, the development of polymeric nanoformulations as carrier for a new class of anti-
infective drugs, such as AMPs, will be presented and discussed. After a brief description of the 
major and more conventional classes of antimicrobial polymer-based materials, this review will 
focus on polymeric materials, with emphasis on those intrinsically endowed with antimicrobial 
activity, as fundamental constituents of AMPs loaded nanocarriers, towards the development of a 
novel therapeutic approach for the treatment of antibiotic resistant infections. 
 
Antimicrobial polymer-based materials 
 
It is generally assumed that an antimicrobial polymer is a polymer exerting a bactericidal activity. 
This generates a wide and heterogeneous category of polymers with different chemical composition 
and active towards various microorganisms. Some antimicrobial polymers are highly attractive 
candidates for the development of new antimicrobial nanostructured delivery systems, as they 
would likely be able to confer to the nanosystems itself a biological activity, opening up 
possibilities for antibacterial synergism between the nanocarrier and the loaded cargo. In fact, 
antimicrobial biomaterials could exert their own antimicrobial activity when utilized for the 
formulation of bactericidal drug delivery systems, as well as resist to microbial colonization when 
employed for the development of biomedical devices [5, 6]. As an instance, anti-infective 
biomaterials have progressively become a primary strategy to prevent medical device-associated 
infections, after the latest achieved improvements in terms of aseptic techniques, sterility control 
and antimicrobial prophylaxis [7].  
The use of antimicrobial polymers holds promises to enhance the efficacy of some existing 
antimicrobial agents, minimize their residual toxicity, increase their efficiency and selectivity and 

































































prolong their lifetime [8]. The requirements that antimicrobial biomaterials need to cover are very 
broad, primarily depending on the material application. The ideal antimicrobial polymer should be 
easily and inexpensively synthesized, stable in long-term usage and at the temperature of its 
application, not decomposing to and/or emitting toxic sub-products, not toxic or irritating and 
biocidal to a broad spectrum of pathogenic microorganisms in brief times of contacts [9]. 
Many factors are known to affect the bactericidal activity of antimicrobial polymers, comprising, 
among the others, molecular weight, hydrophilic-hydrophobic ratio, carried charge and, if the 
polymer brings antimicrobial moieties, the key role of the spacer length.  
The first and most widely investigated antimicrobial polymers are charged polymers inhibiting the 
adhesion of bacteria (negatively charged polymers) or their growth (positively charged polymers). 
Among those, important observations were performed on acidic or quaternarized acrylic and 
methacrylic polymers [10] and quaternary ammonium salts (QAS) pending from various polymer 
types (polysiloxanes [11]; polyethyleneimine [12], poly(oxazoline)s [13] and polystyrene [14]), 
with the bactericidal activity strictly affected by the adopted spacers (amphiphilic balance, length of 
the alkyl chain, balance of cationic moieties and hydrophobic groups). Variations in the amphiphilic 
balance lead to different affinities to the bacterial membranes favor the diffusion through the 
membranes and influence the bactericidal activity/cytotoxicity ratio. Alternatively to antimicrobial 
polymers with pendant quaternary ammonium/phosphonium salt (QAS/QPS), cationic polymers 
containing QAS or QPS in the backbone have been deeply investigated. Such polymers, known as 
linear or comb-like ionene polymers, are capable of forming complexes with heparin and DNA, 
accompanied by adhesion, aggregation and lysis of bacterial cells. Additionally, ionenes with rigid 
spacers exhibited stronger interaction with phospholipid bilayers; longer hydrophobic segments, 
with lower charge densities, exhibited more effectively biocidal ability versus yeast protoplast than 
those with higher charge densities [15]. 
Further than QAS containing polymers, several antimicrobial structures have been investigated 
through the years. Significant roles play guanidine containing polymers; polymers mimicking 
natural peptides, such as arylamide and phenylene ethynylene backbone polymers and 
polynorbornene derivatives; halogen polymers, such as fluorine- and chlorine-containing polymers 
and polymeric N-halamines; polymers containing phospho and sulfo derivatives; organometallic 
polymers; and phenol/benzoic acid derivative polymers [6] (Table 1). 
Polymer-based materials, exerting a microbicidal action can be obtained by chemical modification 
of polymer and addition of low molecular weight antimicrobial compounds, addition of metal 
nanoparticles (polymer nanocomposites), insertion of oxides or inclusion of antimicrobial modified 
inorganic systems [16]. 
Antimicrobial agents containing reactive functional groups (hydroxyl, carboxyl or amino groups) 
can be covalently linked to a variety of polymerizable derivatives. Most of the synthesized drug-
bearing monomers are acrylic types of pharmaceutically active molecules that can be 
copolymerized obtaining different drug contents and hydrophobic/hydrophilic branches. Otherwise, 
antimicrobial agents have been immobilized on synthetic preformed polymers or naturally 
occurring polymers [9].  
The combination of polymeric-based materials with antimicrobial inorganic systems has also been 
widely studied. Silver nanoparticles are probably the metal particles most used as antimicrobial 
agent in polymeric nanocomposites. Silver and its compounds are well known for their broad 
antimicrobial spectrum against bacteria, fungi and viruses [17]. Several antimicrobial polymer 
nanocomposites have been prepared by mixing preformed particles with polymers. Nanocomposites 

































































of polyamide [18] and polypropylene [19] containing silver powder were produced by melt 
processing; multilayer films with antimicrobial properties were prepared from polyethylene 
(PE)/silver nanocomposites by the dispersion of silver powders in the polymeric solution. The Ag
+
 
release and the subsequent antimicrobial activity were found to be dependent on the silver 
nanoparticles content and on the deposition method [20]. Polymeric nanotubes and nanofibers [21] 
with silver nanoparticles have been prepared by chemical oxidation polymerization of rhodanine. 
The synthesized materials showed excellent antimicrobial activity against Escherichia coli, 
Staphylococcus aureus and Candida albicans, caused by the combined activity of silver and 
rhodanine. Also copper particles are known for their antimicrobial activity [22] and were employed 
for the preparation of polypropylene (PP) nanocomposites by melt mixed method. Composites with 
only 1% (v/v) of Cu were able to kill 99.9% of bacteria after 4 h of contact [23]. Several studies 
were also focused on the incorporation of copper nanoparticles onto the surface of polymers. 
Copper ion implantation by plasma immersion was employed to create antibacterial surface on PEs, 
exhibiting excellent long-term antibacterial effects against E. coli and S. aureus [24].  
The insertion of oxides in polymers allows for photocatalytic disinfection or photo-killing, an 
emerging powerful technologies for bacterial killing [25]. Titanium dioxide TiO2-anatase is the 
most broadly used photocatalytic, generating energy-rich electron-hole pairs able to degrade cell 
components of microorganisms. Among several possibilities, titanium can be supported on 
polymers. Zinc oxide (ZnO) is also a photocatalyst, with a bactericidal mechanism of action similar 
to TiO2-anatase. ZnO nanoparticles have been incorporated into thermoplastic polymers polyamide 
6 and low density PE [26]: in both cases the nanocomposites showed great antimicrobial activity 
with low content of ZnO, 1% (w/w), which enhanced as the ZnO increased in the nanocomposite. 
Montmorillonite is an antimicrobial modified inorganic system explored in combination with 
polymeric materials. Organo-montmorillonite with antimicrobial properties was prepared from Na
+
-
montmorillonite and chlorhexidine acetate [27]. This was blended with polydimethylsiloxane 
(PDMS) to produce nanocomposites films. The antibacterial activity was investigated by mean of 
the inhibitory zone tests, revealing a strong inhibition of the growth of E. coli and S. aureus. 
Commercially available organoclay montmorillonites modified with cationic surfactants were also 




Antimicrobial peptides (AMPs) are a large and diverse group of molecules, utilized as nature’s 
antibiotics and produced constitutively or in response to infections in virtually every organism [29].  
Generally they are small (with a varying number of amino acids from 5 to over a hundred) mainly 
cationic and amphipathic with a considerable diversity in sequence and structure. Based on their 
molecular masses, secondary and tertiary structures and amino acid composition, AMPs can be 
classified into various categories comprising peptides with α-helix structures (e.g. human 
cathelicidin), peptides with β-sheet structures stabilized by disulfide bridges (e.g. human defensins), 
peptides with extended structures (e.g. the bovine AMP indolicidin); and peptides with loop 
structures, like cyclic defensins found in Rhesus macaques. At present more than 2500 AMPs from 
both living prokaryotic and eukaryotic organisms have been reported. Updated databases [30] of 
AMPs structures and activities are available on line at: http://aps.unmc.edu/AP/main.php [105] and 
http://www.biomedicine.org.ge/dbaasp [106] The mechanisms of the antimicrobial action of AMPs 
are complex and still not fully understood. It is widely accepted that most cationic AMPs establish 

































































electrostatic interactions with the negatively charged phospholipid head groups of bacterial 
membranes followed by insertion in and disruption of the lipid bilayer. Several models of AMP-
membranes interaction have been proposed (Figure1). In the “barrel-stave” model, AMPs assemble 
to form pores across the membrane so that their hydrophobic moieties face the lipid bilayer, while 
their hydrophobic parts face the pore’s lumen. In the “carpet model” peptides cover the outer side of 
the membrane like a carpet, and then reorient themselves and place in the hydrophobic core of the 
membrane forming micelle-like units and acting like a detergent [31]. Moreover, it is suggested that 
some AMPs do not cause cell membrane disruption, but rather act by crossing the membrane and 
accumulating in the cytoplasm of bacterial cells where they interfere with the activity of 
intracellular target. 
In the era of antibiotic resistance, AMPs are widely considered among the most promising lead 
compounds for the development of new anti-infective drugs. Indeed, the potential advantages of 
AMPs as antimicrobial drugs are numerous (Figure 2). They usually exhibit a fast and broad-
spectrum of activity against a wide range of microorganisms, including Gram-negative and Gram-
positive bacteria, protozoa, yeast, fungi and viruses [32] (Table 2). Notably, many AMPs are also 
active against multi-drug-resistant strains [33-35] and synergize when tested in combination with 
conventional antibiotics [36]. Furthermore, their interactions with bacterial components usually do 
not involve specific protein binding sites and thus, they are believed to induce resistance at much 
lower rate than conventional antibiotics. Beside their direct antimicrobial properties, AMPs often 
display immunomodulatory activities like chemotaxis, modulation of cytokine and chemokine 
expression, leukocyte activation and others, suggesting that, in vivo, they may also indirectly 
participate to the eradication of an infection [37]. Many AMPs can promote healing processes by 
stimulating cellular proliferation or angiogenesis, thus potentially contributing to tissue repair 
during the course of an infection [38]. Finally, AMPs can be chemically manipulated (by amino 
acid substitution, introduction of D or non-natural amino acids, expression as fusion proteins, 
combination of different functional domains etc.) to develop derivatives of natural peptides or de 
novo designed molecules with improved pharmacological profiles [ref 39]. Critical features for 
peptide design are optimal size, charge, hydrophobicity, the positioning of shape-modifying amino 
acids (proline, glycine) and the presence of amino acids with affinity for membrane interfaces 
(tryptophan) [40]. 
Despite these numerous desirable characteristics, many limitations still hamper AMP- 
pharmaceutical development (Figure 2).  For instance, the unspecific action of AMPs on the 
bacterial membranes could potentially be harmful to mammalian cell membranes as well, 
determining a low cytocompatibility, at therapeutic concentrations. Inactivation by biological fluids 
[41], sensitivity to host and/or bacterial proteases [42] (with consequent decrease of their 
antimicrobial potency in physiological environments) and high manufacturing costs are additional 
limits in the use of AMPs as future drugs. Thus, the current challenge in AMP therapeutic 
development is to produce them at a reasonable cost as well as to overcome the obstacles that still 
hamper their clinical employment, especially as systemic drugs. In this regard, the entrapment of 
AMPs in suitable micro-nanostructures, possibly endowed with their own antimicrobial activity, 
may represent a promising approach with the potential of minimizing the peptides toxicity towards 
mammalian cells [43], protecting them by proteolysis and un-wanted interactions with biological 
fluids, and ensuring a controlled and long-lasting release of the entrapped molecules (Figure 2).  
 
 


































































Clinical applications of AMPs: topical and local delivery 
In spite of the potential possibilities offered by the discovery of thousands of natural peptides and 
the design of millions of synthetic peptide, relatively few AMPs, selected on the basis of promising 
outcomes of in vitro and animal studies, have actually proceeded into clinical trials. Both positive 
and negative experiences have been observed in clinical trials.  
Pexiganan (MSI-78), a synthetic 22-amino acid analogue of Magainin II, was the first antimicrobial 
peptide to undergo commercial development. It had demonstrated excellent in vitro broad-spectrum 
activity against 3109 bacterial clinical isolates, with no selection of resistant mutants after repeated 
passages at sub-inhibitory concentrations. Two Phase III clinical trials involving 835 diabetic 
patients with infected foot ulcers showed an improvement in 90% of patients using either Pexiganan 
or conventional oral Ofloxacin. Eradication of pathogens was obtained in 82% of the Ofloxacin 
recipients compared to 66% of Pexiganan recipients, at the end of the therapy. In 1999, FDA 
approval was denied not because of a lack of activity but rather for an inability to demonstrate an 
advantage over existing therapeutics (i.e. non-equivalence) [44]. 
Another negative result involves Nisalpin™, the trade name for bacterial Nisin, subjected to Phase I 
clinical trials on Helicobacter pylori infections with encouraging results, but then abandoned.  
Despite these negative experiences, there is ample cause for optimism around AMPs, at least as 
topical/local agents. Cationic peptides Polymyxin B and Gramicidin S, considered too toxic for 
systemic use, have been used in combination for many years in various topical formulations, 
including wound creams and eye/ear drops. Several attempts have been made in order to reduce 
polymyxins and gramicidins toxicity, unsuccessfully to date [45]. Clinical efficacy has been 
observed with MX-226/Omeganan in the prevention of catheter-associated infections, but issues 
with clinical trial design and endpoints have precluded licensure to date. Other peptides that 
advanced into Phase III clinical-efficacy trials are the pig Protegrin derivative IB-367, Iseganan, 
indicated for the treatment of oral mucositis, and the human bactericidal permeability protein 
derivative rBPI23, Neuprex, indicated for treating sepsis [46]. In addition to the above peptides, 
many other molecules are proceeding through discovery, development and clinical trials [47] (Table 
3). 
The potential systemic applications of AMPs has been limited by several major issues such as  the 
poor pharmacokinetics related to their susceptibility to proteases and other clearance mechanisms, 
unknown systemic toxicity and cost of goods. At present, clinical trials aimed at exploiting the 
direct antimicrobial activity of AMPs have been restricted to topical applications for the treatment 
of surface infections.  
In addition, the high cost of manufacturing peptides has limited both the testing and development of 
large numbers of variants and the potential clinical targets to which these molecules can be applied. 
However, increasingly practical recombinant DNA expression strategies, the use of peptide array 
and advanced computational strategies are starting to impact on the cost of goods [48]. Regarding 
AMPs lability to proteases, leading to potentially unfavourable pharmacokinetics, several solutions 
have been proposed, including: the use of unusual or D- (rather than natural L-) amino acids (which 
renders peptides protease-resistant), the use of non-peptidic backbones (peptidomimetics), 
formulations to improve stability (e.g. liposomes, nanoparticles) or the chemical modification of 
peptides to create protease-resistant (and/or less toxic) pro-drug molecules [49]. Although AMPs 
seem to have a lesser ability to disrupt eukaryotic membranes, lacking negatively charged lipids on 

































































the surface, systemic toxicity is an issue yet to be properly addressed. Research on antimicrobial 
peptides urgently needs careful investigations aimed at evaluating subtle toxicities associated with 





Nanostructures for the delivery of antimicrobial peptides 
 
The formulation of peptides and proteins into nanocarriers has been extensively studied over the 
past decades and among those, few AMPs have been included into drug delivery nanostructures 
[50]. The most commonly applied nanoformulation techniques are easily classified into two main 
categories, whether they involve the in-situ polymerization of the macromolecules (emulsion and 
dispersion polymerization, interfacial polymerization/polyaddition/polycondensation) or more 
commonly, the direct use of preformed polymers. Due to their lability, the retention of activity, 
structural identity and stability of the peptides after encapsulation are basic concerns in the 
development of peptide-loaded nanostructures. Reasonably, the less aggressive technics are 
selected, e.g. emulsion-solvent evaporation, phase separation, salting out, dialysis methods, 
ionotropic gelation and self-assembling [51, 52]. 
AMPs have been formulated into several nanostructures up to date, including lipid nanovesicles, 
nanofibers, coated metallic nanoparticles, self-assembled structures, hydrogels and polymeric 
nanoparticles (Figure 3). 
 Lipid nanovesicles and liposomes, can be employed for the delivery of water-soluble, lipid-
soluble or amphiphilic molecules due to the presence of both lipidic and aqueous phases in their 
structure [53]. Commonly, they are obtained by thin film hydration techniques frequently associated 
to additional sonication or membrane extrusion. Considering that the main mechanism of action of 
AMPs toward bacteria is the destabilization of the phospholipid membrane, the use of lipid vesicles 
for the delivery of AMPs introduces several questions regarding the stability of the carrier itself and 
the obtained antimicrobial activity of the formulation. Indeed, lipid composition of the vesicles 
affects the interaction with the biological membranes, favouring the repulsion, adhesion, fusion or 
internalization of the carrier. Lipid composition can also affect its susceptibility to perturbation 
caused by the loaded AMP, favouring then its release from the carrier itself. These aspects were 
investigated by varying the composition of phosphatidylcholine (PC) based vesicles loaded with 
Nisin, for the inhibition of Listeria monocytogenes growth for milk conservation applications, and 
reviewed in Malheiros et.al. [54]. Food application of Nisin was further investigated by preparing 
liposomes made with marine lecithin (ML) or soy lecithin (SL). SL improved Nisin loading, 
physical stability monitored at 4 °C revealing pore-formation by the AMP and fusion phenomenon 
after 20 weeks. Antimicrobial assay revealed that blend of unencapsulated/free and encapsulated 
nisin (1:1) exhibited a better control of L. monocytogenes as compared to free or 100% encapsulated 
nisin alone [55]. Recently, the LL-37 (human AMP) has been encapsulated in nanostructured lipid 
carriers (NLCs), produced by the melt-emulsification method. LL-37 has a broad spectrum of 
antimicrobial activity, but it is also able to modulate wound healing by participating in 
angiogenesis, epithelial cell migration and proliferation, and immune response. The described 
carrier showed lack of in vitro cytotoxicity and the encapsulated LL-37 maintained its bioactivity, 
as it was evidenced by assessing the antimicrobial activity against E. coli and the in vivo wound 

































































healing repairing, in a full thickness wound db/db mice model [56].  Similarly, pegylated-liposomes 
loaded with LL-37 were evaluated against herpes simplex virus 1 (HSV-1) and compared to 
analogous liposomes loaded with indolicidin. The LL-37 liposomes were rapidly taken up by 
human keratinocyte cell line (HaCaT), remained intact within the cells, and the release of the active 
peptide within the cytoplasm was followed by the migration of the vesicles' lipids to the plasma 
membrane. Furthermore, in 3D epidermis model (immortalized primary keratinocytes) liposomal 
LL-37 treatment was able to protect the epidermis by inhibiting HSV-1 infection, and without 
cytotoxic induction [57]. 
Additional lipidic formulations have been investigated for lung delivery applications. Anionic 
dimyristoyl phosphatidylcholine (DMPC) and dimyristoyl phosphatidylglycerol (DMPG) (3:1 
molar ratio) liposomes encapsulated high levels of the cationic α-helical AMP CM3 were delivered 
by nebulization to the lungs of rats chronically infected with Pseudomonas aeruginosa. A reduction 
in the AMP toxicity and an enhanced protection of the peptide against proteolytic degradation were 
observed [58]. 
 Nanofibers, polymeric fibres arranged into woven or no-woven meshes has a large specific 
surface area, which increase by reducing nanofibers diameter. Their functionality is generally 
affected also by the interfibres spaces and structure geometry, affecting eventual permeability, 
swellability, mass transport and degradability as well as mechanical properties. Such advantages, 
together with high drug loading and flexibility in materials selection, suggested the use of 
nanofibrous constructs as drug delivery devices, dressings, coatings, and tissue regeneration 
applications [59]. Concerning the loading of AMPs, electrospinning has been the mostly applied. 
Both natural and synthetic polymers can be employed for their development, such as chitin and 
chitosan, silk fibroin, poly(L-lactic acid), poly(vinyl alcohol) and polyurethane. Also in this field, 
the development of antimicrobial meshes exploiting the activity of AMPs represents an alternative 
to the use of antibiotic eluting devices [60].   
AMPs loaded electrospun meshes have been investigated for various applications, including food 
preservation, prevention of microbial adhesion on surfaces and wound dressing. The use of Nisin 
for food applications has been investigated not only by liposomal formulations, but also as loaded 
into phosphorylated soybean protein isolate/poly(l-lactic acid)/zirconium dioxide (Nisin-
PSPI/PLLA/ZrO2) nanofibrous membranes. The device displayed controlled release and good 
antimicrobial activity against Staphylococcus aureus [61]. Also the AMP Pleurocidin has been 
evaluated as food preservative. Its loading into poly(vinyl alcohol) electrospun nanofibers provided 
a sustained release after a temperature dependent burst release. Interesting, the inhibition activity 
toward E. coli was assessed in a real food system [62]. Electrospun polyethylene oxide nanofibers 
were developed for the encapsulation of Plantaricin 423, for food and medical applications. The 
peptide maintained its antimicrobial activity after electrospinning and the loaded nanofibers 
successfully inhibited the growth of Enterococcus faecium and Lactobacillus sakei [63]. 
Another strategy envisages the immobilization of the AMP on preformed electrospun meshes. 
Magainin II (Mag II) was covalently immobilized on poly(lactide-co-glycolide) (PLGA) and 
PLGA/gelatin electrospun fibrous membranes. In this case bacterial adhesion tests revealed that the 
attachment and survival of microorganisms were inhibited [64]. This approach gives the possibility 
to confer multiple functions to a membrane device, as investigated with a bilayer membrane for 
tissue engineering application [65].   
Antimicrobial wound-dressings based on the incorporation of AMPs into polyelectrolyte multilayer 
films were obtained by alternate deposition of polycation (chitosan) and polyanion (alginic acid 

































































sodium salt) over cotton gauzes. The AMPs (β-Defensin-1, Dermaseptin, Cys-LC-LL-37, Magainin 
1) used in this work provided a good antimicrobial effect without cytotoxicity to human dermal 
fibroblasts at the tested concentrations [66]. 
 Metallic nanoparticles (MNPs) could serve as potential nanocarriers for AMPs, as well. 
Metallic nanoparticles, based on silver as an instance, have been known for their intrinsic 
antimicrobial properties and used in the medical field for antimicrobial applications for years [67]. 
The exact mechanisms of MNPs toxicity against bacteria are not completely understood. However, 
NPs action may result in bacterial cell wall or membrane damage or be responsible for detrimental 
changes in cellular organelles. Generally, the good antibacterial properties of nanostructured 
materials arise from their superior surface area, providing greater contact with bacterial cells [68]. 
In most cases, antibacterial nanostructures are able to attach to the bacterial surface by electrostatic 
interactions and disrupt its integrity. The mechanisms of NPs toxicity depend on NPs composition, 
surface modifications and intrinsic properties and on the target bacterial species [69]. 
Multifunctional nanoparticles can be created by mean of entrapment, coupling or absorption of 
specific molecules like AMPs onto MNPs, thus combining the antimicrobial activity of both the 
nanoparticles and the selected AMP. As an instance, magnetic nickel nanoparticles uniformly 
coated with a nanolayer biofilm of polyacrylic acid were used to immobilize the antimicrobial 
peptide LL-37. Nanoparticles coupled to a critic concentration of LL-37 peptide were able to 
effectively inhibit E. coli propagation [70]. 
 Currently, high attention is devoted to self-assembly structures that can be formed by natural 
or synthetic peptides in determined conditions. Self-assembly peptides exhibit several attractive 
features for drug delivery applications. Short peptides, ranging from single di-peptides to small 
linear/cyclic peptides, can self-assemble in nanotubular structures [71]. Nanotubes can be 
internalized by cells through endocytosis, upon spontaneous conversion into vesicles. Self-
assembled cyclic peptides usually have numerous alternating D and L amino acids and stack 
through extensive intermolecular hydrogen bonding to form extended cylindrical structures. The 
ability to adjust the outer surface properties enables nanotube arrangement in a variety of different 
environments, such as in bulk solution, in the solid state and as transmembrane pores in the 
bacterial membrane, possibly acting as efficient ion channels. The cationic peptide KSL, active 
against a wide range of microorganisms, was selected as a model to catalyze self-immobilization on 
bionanocomposites (silica or titania nanoparticles). A self-encapsulating method was developed and 
sustained diffusion of active peptide was achieved in order to deliver a controlled dose of KSL over 
an extended period of time. The developed AMP-loaded nanoparticles retained biocidal activity 
against Staphylococcus epidermidis and Staphylococcus aureus, protected the peptide from 
proteolytic degradation and facilitated a continuous release of the AMP over time. The effect 
towards S. aureus suggested that the developed KSL bioinorganic nanoparticles exert a stronger 
biocidal effect compared to the free peptide [72].  
Antimicrobial core-shell structured nanoparticles were obtained by self-assembly of the synthetic 
amphiphilic peptide CG3R6TAT. The formation of nanoparticles was found to strongly enhance the 
peptide antimicrobial activity compared to the unassembled peptide counterpart. The developed 
nanoparticles exhibited a broad spectrum of antimicrobial activities, which efficiently inhibited the 
growth of various types of drug-sensitive and drug-resistant Gram-positive bacteria with low 
minimum inhibitory concentration (MIC) values, yet inducing relatively low haemolysis. Moreover, 
they displayed a high therapeutic index against S. aureus infections in a mouse model and were able 
to cross the blood-brain barrier (BBB) in a S. aureus-induced meningitis rabbit model, suppressing 

































































bacterial growth in the brain. These nanoparticles may provide an efficient antimicrobial tool for the 
treatment of brain infections and other infectious diseases [73]. Moreover, some AMPs are able to 
naturally form self-assembled nanostructures, such as Linocin M18, which spontaneously forms 20-
30 nm particles, Iturin A, which has a great propensity to self-associate in 150 nm-vesicles, and 
Lactacin F, giving 25-50 nm micelles [50]. Self-assembly propensity of AMPs could be exploited to 
develop more efficient pharmaceutical forms of these peptides, improving their stability and 
pharmacokinetics.  
 Hydrogels have been investigated for AMPs delivery, as well. Antimicrobial hydrogels 
could have a massive impact in wound healing: when infections prevent tissue regeneration at the 
site of injury, biocompatible hydrogels carrying AMP could accelerate the healing by allowing cells 
attachment and infiltration. The synthetic peptide PXL150, exhibiting a broad-spectrum 
antimicrobial activity, was incorporated into a hydroxypropyl cellulose gel for topical treatment of 
infected wounds at surgical sites [74]. PXL150, a novel short synthetic AMP active against Gram-
positive and Gram-negative strains, including methicillin-resistant S. aureus (MRSA), was slowly 
released from the hydrogel in vivo on the wound site. 
 Regarding polymeric NPs, PLGA nanoparticles have successfully proved to be efficient 
carriers for large biomolecules such as vaccines and proteins, for the treatment of various diseases 
[75]. In fact, PLGA is fully biodegradable, biocompatible, has versatile degradation kinetics and is 
approved by the European Medical Agency and Food and Drug Administration as an excipient for 
parenteral products. Chereddy et al. [76] developed PLGA NPs by mean of the emulsion-solvent 
evaporation technique for the encapsulation of the antimicrobial peptide LL-37 for wound healing 
applications. LL-37 exerts different functions like broad antimicrobial activity, modulation of pro-
inflammatory response, promotion of wound healing and angiogenesis [76]. The PLGA-based 
sustained delivery of LL-37 significantly improved the wound healing activity, compared to PLGA 
or LL-37 alone. The healing effect of PLGA-LL-37 NPs included higher re-epithelialization, 
granulation tissue formation, immunomodulation and improved angiogenesis. Wound healing 
promotion by PLGA-based drug delivery systems was found to be dependent on the sustained 
release of bioactive LL-37 as well as on the intrinsic activity of lactate released from PLGA. 
Recently, D’Angelo et al. [77] reported a method to engineer PLGA nanoparticles loaded with a 
model cationic peptide, namely colistin, for lung delivery in cystic fibrosis. The surface of PLGA 
nanoparticles was engineered with polyvinyl alcohol or chitosan to promote colistin diffusion 
through artificial mucus. Moreover the embedding of nanoparticles in lactose microparticles 
allowed obtaining a dry powder with promising properties for inhalation.  
Poly(lactic acid) (PLA) was investigated as well: nisin was encapsulated in poly(L-lactic acid) 
nanoparticles prepared by mean of the precipitation method, maintaining its sustained antimicrobial 
activity for up to 45 days [78]. Niece et al. [79] investigated the employment of poly(alkylacrylic 
acid) polymers grafted with poly(alkylene oxides) for the development of cationic AMPs delivery 
systems. Poly(alkylacrylic acid)s have pH-dependent conformational properties that promote 
membrane penetration and endosomal escape, while the poly(alkylene oxides) chains provide steric 
stabilization and reticuloendothelial system (RES) protection. Protective polyelectrolyte complexes 
were formed with a model cationic AMP, KSL-W. The binding and release characteristics of the 
peptide from the nanocomplexes could be tuned by varying graft density, polymer backbone and 
charge ratio. Depending on the graft density and charge ratio, these peptide/copolymer 
nanostructures were able to provide substantial peptide protection from degradation in human 

































































plasma for up to 24 hours, retaining from 25 to 100% of the peptide biological activity against 
planktonic S. aureus.  
 Natural polymers-based systems have been investigated for AMPs formulation. Gelatin is a 
denatured protein derived from collagen, greatly and safely used in pharmaceuticals, cosmetics, and 
food products [80]. A slow release system based on biodegradable freeze-dried cationic gelatin 
microspheres loaded with the small and angiogenic α-helical cationic peptide AG-30, was 
developed as potential treatment for ischemic diseases [43]. AG-30 displays its antimicrobial 
activity by inducing the lysis of bacterial cells without affecting eukaryotic cells and at the same 
time is able to induce angiogenesis, thus allowing the concomitant killing of bacteria and 
enhancement of endothelial cell growth. The slow-release formulation in gelatin microspheres was 
effective in protecting the peptide form proteases degradation in vivo, allowing its prolonged 
delivery in a mouse ischemic hind limb model, for angiogenic and antimicrobial treatment.  
A water-soluble glycogen-like α-D-glucan derived from plants, namely Phytoglycogen (PGG), was 
selected for the development of nanoparticles for the controlled release of nisin [81]. PGG 
polysaccharide nanoparticles subjected to β-amylolysis and subsequent succinate- or octenyl 
succinate-substitution, combined or not with β-dextrin (PGB), were employed to develop the novel 
nisin loaded nanocarriers. PGB-based nanoparticles showed enhanced ability to retain AMP activity 
with respect to the PGG-based ones, regardless of the substitution with succinate or octenyl 
succinate. The increase of nisin loading achieved with the surface thinning of nanoparticle by β-
amylolysis lead to a prolonged activity of the formulation against L. monocytogenes.  
Improved features have been achieved by using antimicrobial polymers for AMP encapsulation. 
Chitosan has been known for years for its antibacterial properties, which along with its good 
biocompatibility and biodegradability, make it an excellent candidate for AMPs delivery [82, 83]. 
Chitosan nanoparticles were recently developed for the controlled release of the AMP temporin B 
(TB) [84]. The AMP was released from the NPs in vitro in a controlled and linear manner, and the 
encapsulation of temporin B in chitosan NPs proved to significantly reduce the peptide’s 
cytotoxicity towards mammalian cells. Additionally, the TB-loaded nanocarrier evidenced a 
sustained antibacterial action against various strains of S. epidermidis, including four clinical 
isolates for at least 4 days, with up to 4-log reduction in the number of viable bacteria compared to 
plain chitosan NPs and plain TB. The developed TB-loaded nanocarriers combined the 
antimicrobial properties of chitosan with those of the loaded AMP: a sustained antibacterial activity 
was ensured by an initial “burst” effect of the intrinsic antimicrobial polymer, combined with the 
gradual release of TB that further reduced the viable bacteria. Chitosan NPs would act as carrier for 
the encapsulated TB, delivering it directly to the bacterial surface while preventing its inactivation 
by interaction with medium components or dead bacteria; the achievement of a high local 
concentration of the peptide would be addressed by the release of TB at the bacterial surface, 
rapidly causing cell death. If this was the case, peptide concentrations below those needed to ensure 
a bactericidal effect of the free peptide, would be sufficient to cause cell death.  
These results suggest that the development of targeted nanoparticles loaded with AMPs could 
maximize their bactericidal effect, releasing the peptide directly to the site of action (bacterial 
membrane), allowing for minimum peptide concentration and maximum microbicidal activity. NPs 
targeting could be achieved by STAMPs (Specifically Targeted Antimicrobial Peptides) 
conjugation on the NPs surface [85]. A typical STAMP molecule consists of two functionally 
independent moieties conjoined in a linear peptide sequence: a non-specific antimicrobial peptide 
serves as the killing moiety while a species specific binding peptide comprises the target moiety. 

































































The target moiety provides the specific binding to a selected pathogen and facilitates the targeted 
delivery of the attached AMP. Nowadays, STAMPs are available for Streptococcus mutans and 
against Pseudomonas spp [86, 87]. 
 
Difficulties in generating or obtaining adequate amount of peptides together with the unavailability 
of established animal models strongly limited pre-clinical studies with encapsulated AMPs. To date, 
only very limited number of formulations have undergone in vivo pre-clinical or clinical trials. 
Examples comprise the AG-30 loaded gelatin microspheres for angiogenic and antimicrobial 
purposes [43], the PXL 150/hydroxypropyl cellulose gel for the treatment of wound infections [74] 
and cartridges of immobilized Polymyxin B for septic shock therapy, which showed good results in 




The encapsulation of AMPs in nanocarriers represents an effective tool for controlling their 
exposure to different environmental stresses typically encountered in biological systems, thus 
improving the peptides stability, efficacy and biodistribution. Nowadays, AMPs have been 
formulated in nanostructures by various methods based on different synthetic and natural materials. 
Investigations on nanoparticles-encapsulated AMPs generally showed advantages in comparison to 
free peptides action, in terms of efficacy, stability and systemic toxicity. These promising results 
should encourage intensive efforts converging on extended preclinical/clinical investigations for the 
development and characterization of AMPs-loaded antibacterial nanostructures.  
Moreover, antimicrobial polymers should be primarily considered for the development of AMPs 
drug delivery systems multifunctional platforms, presently focusing on new antimicrobial lead-
compounds, should additionally deal with nanotherapeutics and nanotools as adjuvant approaches to 
prevent and combat microbial infections. A combined and enhanced antimicrobial action should be 
obtained, being not only the loaded drug, but also the material and the delivery system, bioactive.  
Studies focusing on the mechanism of action of AMPs-loaded antibacterial nanotools should also be 
highly encouraged. AMPs interactions with bacterial membrane have already been investigated by 
mean of fluorescent labelling and electron microscopy analysis, X ray scattering, solid state nuclear 
magnetic resonance (NMR) and differential scanning calorimetry [90, 91]. The mechanism of 
bacterial membrane interaction with loaded antibacterial nanotools is a highly interesting topic of 
study, potentially useful for the development of improved and highly efficient antibacterial 
nanotools. Moreover, fluorescent labelling of AMPs or antimicrobial nanotools could give precious 
information about intracellular trafficking and target of AMPs, which could lead to practical 
improvements in clinical practice of infectious diseases.    
In addition to basic research, more efforts should be focused on pre-clinical and clinical studies. 
The application and administration route of AMPs-loaded nanostructures should be carefully 
evaluated during the ideation and development of these therapeutic nanotools and particular 
attention should be devoted to clinical trials involving the developed systems, as that was the 
critical and limiting phase up to date. 
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 Figure 1. Mechanisms of bacterial membrane disruption by AMPs. 
Figure 2. Opportunities and limits offered by antimicrobial peptides (AMPs) as future antibiotics, and 
possibilities offered by nanomaterials as delivery systems to improve AMPs’ clinical potential. The 
development of AMPs as new drugs may largely benefit from the use of nanotechnologies, improving their 
delivery to the infectious site, stability in biological fluids, cyto-compatibility, and penetration trough mucus 
and epithelial barriers. In addition, nanoparticles may be endowed with an inherent antimicrobial activity that 
may sum/synergize with that of the loaded AMPs. 
 
 Figure 3. Schematic representation of nanostructures developed for the delivery of AMPs. 
 



































































Figure 1: Mechanisms of bacterial membrane disruption by AMPs.  
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Figure 2: Opportunities and limits offered by antimicrobial peptides (AMPs) as future antibiotics, and 
possibilities offered by nanomaterials as delivery systems to improve AMPs’ clinical potential. The 
development of AMPs as new drugs may largely benefit from the use of nanotechnologies, improving their 
delivery to the infectious site, stability in biological fluids, cyto-compatibility, and penetration trough mucus 
and epithelial barriers. In addition, nanoparticles may be endowed with an inherent antimicrobial activity 
that may sum/synergize with that of the loaded AMPs  
44x25mm (300 x 300 DPI)  
 
 



































































Figure 3: Schematic representation of nanostructures developed for the delivery of AMPs  
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Table 1. Main classes of polymers displaying antimicrobial activity. 
Class of antimicrobial polymer  Examples Properties 
Guanidine containing polymers 
Oligo/poly-guanidines, polybiguanidines 
[92, 93]. 
High water solubility, 
excellent biocidal efficiency, 
wide antimicrobial spectrum 
and non-toxicity 
Organometallic polymers 
Organotin derivatives, silver polymeric 
complexes, metal (Mn, Co, Cu, Zn) resin 
complexes [6] either in the backbone 
chain or in the pendant groups. 
 
Broad spectrum biocides 
against both bacteria and 
yeasts 
Polymers with quaternary nitrogen atoms 
Polymers containing aromatic or 
heterocyclic structures [94], acrylic and 
methacrylic polymers [95], cationic 
conjugated polyelectrolytes [96], 
polysiloxanes [97], hyperbranched and 
dendritic polymers [98], oxazolines [ 99] 
Broad spectrum activity, 
effective against drug-
resistant bacteria, rapid 
biocidal action 
Polymeric Synthetic Mimics of 
Antimicrobial Peptides (polymeric 
SMAMPs) 
Arylamide and phenylene ethynylene 
backbone polymers, polynorbornene 
derivatives [100] 
Excellent antimicrobial 
activity, tunable selectivity 






acrylate, chlorophenyl methacrilates, 
poly(N-halamines) [101, 102] 
High chemical, thermal, aging 
and weather resistance, 
antimicrobial activity 
associated with their surface 




Poly(styrene sulfonic acid), 
poly(sulfobetaine methacrylate) [103] 
Viral replication inhibition 
(HIV-1, HSV-1), long-term 
active against bacterial 
biofilms 
 
Phenol/benzoic acid derivatives polymers 
Benzaldehyde derivatives, ferulic acid 
copolymers [104] 
Broad spectrum inhibitory 
activities,  


















































































































Activities of AMPs Example AMPs 
Broad spectrum antibacterial 
Protegrin, IB-367, MSI-78, Indolicidin, CEMA, Gramicidin 
S, Magainin II, Polyphemusin, Defensin MV 
Anti Gram-negative bacterial Polymixin B, Colistin, Hinnavin II, Bactenecin 5 
Anti Gram-positive bacterial 
Nisin, Isoform 5, Andropin, Rugosin A, Temporin C, 
Protegrin I 
Synergy with conventional antibiotics 
CEMA, Magainin II, MSI-78, IB-367, Human β-Defensin 3, 
Temporin L 
Antifungal 
OdVP1-2-3, Protegrin, CEMA, Indolicidin, Gramicidin S, 
Polyphemusin, Bactrocerin-1, Drosomycin 
Synergy with conventional antifungal Indolicidin, Hepcidin 20 
Anti endotoxin CEMA, Indolicidin 
Antiviral (HIV, HSV, Dengue-2) Indolicidin, Polyphemusin, Protegrin, RScp 
Anticancer CEMA, Indolicidin, Lasioglossins 
Synergy with conventional anticancer agents Indolicidin 
Wound healing Magainins, PR39 
Antiparasite Magainin II, Indolicidin, Phylloseptins, BMAP-18 
Antimalarial Meucin-24, Gambicin,  Phylloseptin-H1 
































































Table 3. Peptides in commercial development [104, 107]. 
Company AMP or AMP-based drug Stage of development Application 
Ceragenix (US) CSA-13 (AMP-mimic peptide) Preclinical Anti-infective 
Helix Biomedix(US HB-50 (synthetic Cecropin-analog) Preclinical Anti-infective 
Helix Biomedix (US) HB-107 (Cecropin 19-aa fragment) Preclinical Anti-infective 
Novacta Biosystems 
Ltd. (UK) 
Mersacidin Preclinical Gram-positive infections 
Novozymes A/S 
(DK) 
Plectasin (fungal defensin) Preclinical 
Systemic anti-Gram-positive, 






Nosocomial infections, febrile 
neutrophenia 
Lytix Biopharma LTX-109 Phase I-IIa 
MRSA nasal decolonization 
and skin infection 
AM-Pharma (NL) 
hLF-1-11 (derived from human 
lactoferrin 
Phase II complete 
Allogeneic bone marrow stem 
cell transplantation-associated 
infections 
OctoPlus (NL) OP-145 (synthetic LL-37 analog) Phase II complete 
Chronic bacterial middle ear 
infections 
Polymedix (US) PMX-30063 (peptidomimetics)  Phase II complete 
Anti-infectives, antimicrobial 
polymers and coating 
materials 
Xoma (US) 
XOMA 629 (derived from 
permeability-increasing protein) 
Phase IIa Impetigo 









Phase IIIb/Phase II 
Prevention of catheter-related 
infections; dermatology-
related infections 




Available on the 
market 





Available on the 
market 
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